Details of the Drug

General Information of Drug (ID: DML61S4)

Drug Name
ARQ-151
Indication
Disease Entry ICD 11 Status REF
Atopic dermatitis EA80 Phase 3 [1]
Psoriasis vulgaris EA90 Phase 2 [2]
Plaque psoriasis EA90.0 Phase 1/2 [3]
Drug Type
Small molecular drug
Cross-matching ID
PubChem CID
449193
TTD ID
DST04F
Repurposed Drugs (RPD) Click to Jump to the Detailed RPD Information of This Drug

Molecular Interaction Atlas of This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Phosphodiesterase 4 (PDE4) TTV5CGO NOUNIPROTAC Inhibitor [4]
Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This Drug

References

1 ClinicalTrials.gov (NCT04804605) Open Label Extension Trial of PDE4 Inhibition With Roflumilast for the Management of Atopic Dermatitis (INTEGUMENT-OLE). U.S. National Institutes of Health.
2 ClinicalTrials.gov (NCT04746911) Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-216). U.S. National Institutes of Health.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 Trial of Roflumilast Cream for Chronic Plaque Psoriasis. N Engl J Med. 2020 Jul 16;383(3):229-239.